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Abstract
Cyclooxygenase-2 (COX-2) is expressed early in colon carcinogenesis and is known to play a
crucial role in the progress of the disease. Here we show that the regulation of the expression of
this enzyme in a colon cancer cell line, and in patients, is associated with overexpression of the Wnt
pathway-associated proteins, Pontin52/TIP49a and LEF-1. Recently shown to be essential for
transformation via the c-Myc pathway, Pontin52/TIP49a promotes COX-2 expression in tissue
culture and is overexpressed in colon cancer tissue, co-localizing with COX-2 expression in
transformed tissue, relative to paired normal tissue.
Findings
Both genetic and pharmacological studies have shown
that the inducible isoform of cyclooxygenase, cyclooxyge-
nase-2 (COX-2), is expressed early in colon carcinogenesis
and plays a crucial role in the development of this disease
[1]. COX-2 expression is induced early in stromal cells
and subsequently at high levels in epithelial cells, where it
correlates with tumor invasion and clinical outcome [2].
The regulatory pathway responsible for increased expres-
sion of COX-2 in colonic tumors is unknown.
In multiple colon cancer cell lines, COX-2 expression
appears to be constitutive. We have examined promoter
sequences active in constitutive COX-2 expression and
have shown that high basal activity is retained with a pro-
moter containing only the COX-2 TATA box region [3]. A
normal function of the tumor suppressor and cell cycle
regulator p53 is to negatively regulate COX-2 promoter
activity by binding the TATA binding protein in this
region [4]. However, certain colon cancer cell lines that
express wildtype p53 also display high levels of COX-2
mRNA. This suggests that other proteins may be impor-
tant for regulating COX-2 expression. We have focused on
the LoVo colon cancer cell line, as normal COX-2 5'flank-
ing sequences (-1840 to -50 bp) had a 3-fold positive
effect on transcription of a luciferase reporter construct in
this cell line, though not in three other colon cancer cell
lines tested, Colo320HSR, HCA7, LS174T (data not
shown).
COX-2 is known to be a downstream target of the Wnt sig-
naling pathway. The Wnt pathway is highly conserved
evolutionarily and has been implicated in many biologi-
cal processes. Deregulation of this pathway results in the
inappropriate expression of target genes and has been rig-
orously linked to carcinogenesis [5,6]. Signaling through
the Wnt pathway increases expression of COX-2 mRNA,
COX-2 protein, and PGE2 levels [7]. Therefore, candidates
for proteins responsible for maintaining constitutive
COX-2 promoter activity in carcinogenesis include effec-
tors of Wnt signaling. One such protein, Pontin52/
TIP49a, was isolated in an in vitro assay designed to
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identify protein binding partners in human colon cancer
cells, using the N-terminus of the Wnt signaling molecule,
β-catenin, as bait [8].
Pontin52/TIP49a is also known to bind the TATA binding
protein and the oncogenic protein c-myc [8-10]. Further,
Pontin52/TIP49a has been implicated as a key factor in
myc-dependent transformation [10].
In addition to DNA binding, transcription factors func-
tion to recruit other proteins that modulate transcription
and/or alter chromatin structure. In human and animal
cancers, the Myc family of transcription factors is fre-
quently disrupted [11,12]. The N-terminal portion of c-
Myc includes a conserved DNA region, the Myc homology
box II (MBII), that is essential for apoptotic and onco-
genic activities, as well as for blocking differentiation and
stimulating cell proliferation [13-17]. This region binds to
the nuclear factors Pontin52/TIP49a and Reptin52/
TIP49b, homologous proteins found in all eukaryotic
organisms as components of multimeric complexes
thought to function in chromatin remodeling and gene
transcription [10,18-24]. They manifest oppositely-ori-
ented helicase activities [18,25] and appear to play antag-
onistic roles [26]. For example, in a zebrafish study of
heart and gut development, the relative balance of Pon-
tin/Reptin activities regulated the extent of cell growth
during organogenesis in the early embryo [27].
Pontin52/TIP49a and Reptin52/TIP49b form complexes
with c-Myc in vivo and this association depends on the N-
terminal c-Myc domain that is essential for oncogenic
activity [10,28]. A missense mutation in the Pontin52/
TIP49a ATPase motif inhibits the oncogenic activity of c-
Myc, but does not inhibit normal cell growth, indicating
that functional Pontin52/TIP49a protein is an essential
mediator of c-Myc oncogenic transformation [10]. The
Pontin52/TIP49a protein has also been shown to be a key
modulator of apoptotic activity for both c-Myc and E2F1
[28]. The fact that Pontin52/TIP49a can also bind to β-cat-
enin and LEF-1/TCF [8] supports a role for Pontin52/
TIP49a as a cofactor likely to function with diverse tran-
scription factors.
To evaluate the role of Pontin52/TIP49a in the transcrip-
tional regulation of COX-2, we transfected a reporter con-
struct containing 1840 bp of upstream COX-2 sequence
into the LoVo colon cancer cell line along with a control
vector or increasing amounts of a Pontin52/TIP49a
expression construct. A dose-dependent increase in COX-
2 promoter activity was observed when increasing
amounts of Pontin52/TIP49a were co-transfected with the
COX-2 construct (Fig. 1A).
The TCF/LEF transcription factors are downstream com-
ponents of the Wnt signaling cascade [29]. In general,
DNA binding alone is not sufficient for TCF proteins to
activate transcription via this pathway. First, TCFs must
form a complex with β-catenin [30] in which TCF pro-
vides a DNA binding function and β-catenin a transcrip-
tional activation domain [31]. Because COX-2 is a known
Wnt target [7], we examined whether overexpression of
the Wnt pathway protein LEF-1 affected COX-2 promoter
activity.
In Fig. 1B, we show that overexpression of either LEF-1 or
Pontin52/TIP49a modestly increased COX-2 promoter
activity in the LoVo colon cancer cell line. Overexpression
of both proteins had an additive effect on COX-2 pro-
moter activity. Of interest, LEF-1 activation of the COX-2
promoter did not require LEF-1 binding sites for either β-
catenin or DNA (Fig. 1C); thus, this activation of COX-2
expression appears to occur through a novel mechanism.
Previous reports suggest that certain Wnt signaling path-
ways are independent of β-catenin [32,33].
To evaluate the expression of Pontin52/TIP49a and COX-
2 in normal mucosa and colon carcinoma tissues, tissue
samples from seven patients were analyzed by RT-PCR
(Fig. 1D). An increase in the level of Pontin52/TIP49a
mRNA was observed in four of the colon carcinoma sam-
ples, but in none of the samples of normal mucosa. Simi-
larly, in three patients an increase in the level of COX-2
mRNA was observed in carcinoma, but not in normal
colonic tissue. In situ hybridization showed that
Pontin52/TIP49a and COX-2 were co-localized in tissue
sections from individuals previously shown to have up-
regulated levels of both proteins (Fig. 1E). Strong mRNA
hybridization was detected throughout dysplastic epithe-
lium for both Pontin52/TIP49a and COX-2. In contrast,
only low to undetectable levels of hybridization were
observed in normal mucosa with either probe. Thus, these
proteins are both overexpressed and co-localize in colon
carcinoma, a pattern that is compatible with Pontin52/
TIP49a participating in COX-2 expression during
carcinogenesis.
Previous work showing that Pontin52/TIP49a modulates
c-myc-dependent apoptosis [28] may be related to our
finding that Pontin52/TIP49a induces COX-2 expression.
Multiple observations support the conclusion that COX-2
expression during carcinogenesis blocks apoptosis in
response to some stimuli. Thus, the demonstration by
Dugan et al. (2002) that showed a dominant negative
construct of Pontin52/TIP49a caused increased apoptosis
might have reflected decreased expression of COX-2.
We show here a trend toward upregulation of Pontin52/
TIP49a and COX-2 expression in a coordinated fashion.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/42
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COX-2 expression is increased by Pontin52/TIP49a and LEF-1 over-expression; colon cancer tissue shows increased expres- sion and co-localization of Pontin52/TIP49a and COX-2 Figure 1
COX-2 expression is increased by Pontin52/TIP49a and LEF-1 over-expression; colon cancer tissue shows 
increased expression and co-localization of Pontin52/TIP49a and COX-2. (A) Pontin52/TIP49a overexpression 
increases COX-2 promoter activity. Increasing amounts of an expression construct for Pontin52/TIP49a were transiently 
transfected into LoVo cells along with a COX-1840 reporter construct. A dose-dependent increase in COX-2 promoter activ-
ity was observed in co-transfections with Pontin52/TIP49a. (B) The COX-2 promoter is activated in an additive manner by co-
overexpression of LEF-1 and Pontin52/TIP49a. cDNAs for LEF-1 (0.5 µg) and Pontin52/TIP49a (1 µg) were transfected into 
LoVo cells alone or in combination. Data are the means of assays performed in triplicate in each of two independent experi-
ments. RLU: relative light units. (C) LEF-1 activation of the COX-2 promoter is independent of the β-catenin binding region (∆ 
N67) or the DNA-binding HMG domain (HMG; amino acids 300–359) of LEF-1. Transient transfection of LoVo cells with the 
-1840nt COX-2 reporter construct (+) and constructs containing wild type LEF-1 (WT) or the indicated constructs were 
completed. Controls included a COX-2 promoterless reporter, pGL3-basic (c) and LEF-1 vector controls, FLAG or EV3S (v). 
Data are the means of assays performed in triplicate in each of 3 independent experiments. In the LEF-1 transfected cells the 
fold-increase ranged from 1.2 to 2.3 and the average is shown. This response was observed in multiple other experiments, 
using different amounts of transfected cDNA, and in different cells. (D) Reverse transcription PCR was performed with 
cDNAs from paired samples of normal (N) colonic tissue and colon cancer tissue (CA) from each of four patients. The top 
panel shows Pontin52/TIP49a expression; the bottom panel shows COX-2 expression (upper band) relative to a control tem-
plate (β-actin, lower band). The data shown are representative of two experiments. (E) An example of in situ hybridization 
using anti-sense (experimental) and sense (control) probes for Pontin52/TIP49a and COX-2, showing co-expression and up-
regulation of mRNAs for both proteins in a colon cancer sample, compared to normal mucosa from the same patient.
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In one patient, Pontin52/TIP49a mRNA was increased,
but COX-2 mRNA expression levels were comparable in
colon cancer tissue and normal mucosa. Thus, our results
are consistent with a scenario where Pontin52/TIP49a
dysregulation occurs prior to COX-2 overexpression in
carcinogenesis.
Methods
Cell Culture, Transient Transfection
Colon cancer cell lines Colo320HSR, LS174T, and LoVo
(American Type Culture Collection) were grown in RPMI-
1640, MEM, and either Hams F12 or DMEM media,
respectively (Life Technologies, Gibco). HCA7 cells, pro-
vided by Dr. Susan Kirkland (ICRF Histopathology Unit,
London, UK) were grown in high glucose DMEM with
110 mg/l sodium pyruvate. Ten percent fetal bovine
serum and 100 units/ml each of penicillin and streptomy-
cin were used throughout. Cells were grown to 60–85%
confluency before transfection or RNA isolation. For
transfections, LipofectAMINE PLUS (Gibco) was used
according to manufacturer's suggestions. After a 3-hour
transfection, 0.5 ml of 10% FBS/DMEM media was added
and the plates incubated 24–48 hours. Plates were har-
vested, cellular debris was pelleted, and 50 µl dual (firefly
and sea pansy) luciferase assay reagents (Promega) were
added to 50 µl supernatant aliquots and measured in a
luminometer (Dynex Technologies Inc.). For some exper-
iments, firefly luciferase activity was normalized to total
protein concentration (BCA protein assay, Pierce). Exper-
imental constructs containing firefly reporter DNA were
normalized to empty vector sea pansy luciferase controls.
Plasmid Construction
The expression constructs were provided by Dr. Marian
Waterman (Burnham Institute, La Jolla, CA), LEF-1 cDNA
(EV3S vector); Dr. Donald Ayer (Huntsman Cancer Insti-
tute), FLAG-tagged N-terminally deleted LEF-1 constructs;
Dr. Rolf Kemler (Max Plank Institute of Immunobiology,
Freiburg, Germany) [8], Pontin52/TIP49a cDNA (CS2+
vector). A CMV-sea pansy luciferase control plasmid
(pGL3-basic), LEF-1 deleted for the DNA-binding HMG
domain (amino acids 300–359) (EV3S vector), and
Pontin52/TIP49 (pCDNA3 vector) were constructed using
standard techniques. Sequences were analyzed by auto-
mated sequencing.
RNA Isolation, Reverse-Transcription, PCR
Total RNA isolated by the Trizol procedure from either
colon cancer or normal mucosa tissues was reverse tran-
scribed using 1 unit/µg Moloney Murine Leukemia Virus
polymerase (Gibco). Reactions were primed with 5 mM
oligo (dT)12–18 in the presence of 10 mM DTT, 0.5 mM
dNTP, and 0.4 units of RNAse Inhibitor (Promega). Tem-
plate cDNA was amplified by PCR (conditions available
on request).
Tissue In Situ Hybridization
Human tissues were supplied by the Tissue Access and
Imaging Core Facility at Huntsman Cancer Institute. RNA
probes were made by incorporation of biotin-UTP using
an in vitro DIG RNA labeling kit (Boehringer Mannheim).
The probes utilized were: Pontin52/TIP49a antisense, 1
kb; sense, 698 bp; COX-2, antisense and sense 413 bp.
Paraffin embedded tissue of colonic carcinoma and
grossly uninvolved colonic mucosa were prepared and
analyzed as described previously [34].
List of abbreviations
COX-2, cyclooxygenase-2; HMG, high mobility group;
LEF, lymphocyte enhancer factor; PCR, polymerase chain
reaction; PGE2, prostaglandin E2; RT-PCR, reverse tran-
scription PCR; TCF, T-cell factor.
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